PL2667715T3 - Leczenie zaburzeń spektrum autystycznego z wykorzystaniem kwasu glicylo-l- 2-metyloprolilo-l-glutaminowego - Google Patents
Leczenie zaburzeń spektrum autystycznego z wykorzystaniem kwasu glicylo-l- 2-metyloprolilo-l-glutaminowegoInfo
- Publication number
- PL2667715T3 PL2667715T3 PL12739509T PL12739509T PL2667715T3 PL 2667715 T3 PL2667715 T3 PL 2667715T3 PL 12739509 T PL12739509 T PL 12739509T PL 12739509 T PL12739509 T PL 12739509T PL 2667715 T3 PL2667715 T3 PL 2667715T3
- Authority
- PL
- Poland
- Prior art keywords
- methylprolyl
- glycyl
- treatment
- glutamic acid
- autism spectrum
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161462141P | 2011-01-27 | 2011-01-27 | |
US201161492248P | 2011-06-01 | 2011-06-01 | |
EP12739509.3A EP2667715B1 (en) | 2011-01-27 | 2012-01-27 | Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid |
PCT/US2012/000047 WO2012102832A1 (en) | 2011-01-27 | 2012-01-27 | Treatment of autism spectrum disorderes using glycyl-l-2-methylprolyl-l-glutamic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2667715T3 true PL2667715T3 (pl) | 2018-02-28 |
Family
ID=46581110
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL12739509T PL2667715T3 (pl) | 2011-01-27 | 2012-01-27 | Leczenie zaburzeń spektrum autystycznego z wykorzystaniem kwasu glicylo-l- 2-metyloprolilo-l-glutaminowego |
Country Status (19)
Country | Link |
---|---|
US (2) | US9708366B2 (pl) |
EP (1) | EP2667715B1 (pl) |
JP (3) | JP6348283B2 (pl) |
AU (1) | AU2012209466C1 (pl) |
BR (1) | BR112013018898B1 (pl) |
CA (1) | CA2823218C (pl) |
CO (1) | CO6791613A2 (pl) |
CY (1) | CY1119455T1 (pl) |
DK (1) | DK2667715T3 (pl) |
ES (1) | ES2641880T3 (pl) |
HR (1) | HRP20171478T1 (pl) |
HU (1) | HUE036637T2 (pl) |
IL (1) | IL227669B (pl) |
LT (1) | LT2667715T (pl) |
PL (1) | PL2667715T3 (pl) |
PT (1) | PT2667715T (pl) |
RS (1) | RS56461B1 (pl) |
SI (1) | SI2667715T1 (pl) |
WO (1) | WO2012102832A1 (pl) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS56461B1 (sr) | 2011-01-27 | 2018-01-31 | Neuren Pharmaceuticals Ltd | Tretman bolesti iz spektra autizma upotrebom glicil-l-2-metilprolil-l-glutaminske kiseline |
WO2013139861A1 (en) | 2012-03-20 | 2013-09-26 | Luc Montagnier | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
BR112015012506A2 (pt) * | 2012-11-28 | 2017-07-11 | Neuren Pharmaceuticals Ltd | tratamento de transtornos do espectro do autismo usando ácido glicil-l-2-metilprolil-l-glutâmico |
WO2015013397A2 (en) * | 2013-07-25 | 2015-01-29 | Neuren Pharmaceuticals Limited | Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders |
PL3049428T3 (pl) | 2013-09-23 | 2019-07-31 | Dr. August Wolff Gmbh & Co. Kg Arzneimittel | Tripeptydy przeciwzapalne |
BR112016028653A2 (pt) * | 2014-06-06 | 2018-07-10 | Deakin University | métodos de tratamento de doenças e distúrbios neurodesenvolvimentais |
RU2608444C1 (ru) * | 2015-10-02 | 2017-01-18 | Закрытое Акционерное Общество "Алмаз Фарм" | Средство для лечения и профилактики расстройств аутистического спектра |
US20180296647A1 (en) | 2015-10-14 | 2018-10-18 | Kurume University | Prophylactic and therapeutic agent for rett syndrome (rtt) comprising ghrelin as active ingredient |
US11972336B2 (en) | 2015-12-18 | 2024-04-30 | Cognoa, Inc. | Machine learning platform and system for data analysis |
WO2017192906A1 (en) * | 2016-05-04 | 2017-11-09 | Neurotrope Bioscience, Inc. | Methods and compositions for treatment of rett syndrome |
IL268125B2 (en) * | 2017-01-20 | 2023-04-01 | Prilenia Neurotherapeutics Ltd | Pridopidine for the treatment of fragile x syndrome |
CN110622179A (zh) | 2017-02-09 | 2019-12-27 | 科格诺亚公司 | 用于数字个性化医疗的平台和系统 |
US20240024293A1 (en) * | 2019-02-01 | 2024-01-25 | Revivo Therapeutics | Nomethiazoles as a treatment for rett syndrome |
JP7491943B2 (ja) | 2019-03-22 | 2024-05-28 | コグノア,インク. | 個別化されたデジタル治療方法およびデバイス |
AU2020324396A1 (en) * | 2019-08-05 | 2022-03-10 | Neuren Pharmaceuticals Limited | Compositions of trofinetide |
EP4051308A4 (en) * | 2019-10-28 | 2023-08-23 | ACADIA Pharmaceuticals Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RETT SYNDROME |
IT202100004964A1 (it) * | 2021-03-03 | 2022-09-03 | Univ Degli Studi Di Bari Aldo Moro | Agonisti del recettore fpr2 (formyl peptide receptor 2) e loro uso nel trattamento del disturbo dello spettro autistico. |
IL310045A (en) | 2021-07-12 | 2024-03-01 | Acadia Pharm Inc | Crystalline forms of tropintide |
CN114128672B (zh) * | 2021-11-21 | 2023-04-07 | 河南省儿童医院郑州儿童医院 | 一种孤独症大鼠模型的构建方法 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
DE3169595D1 (en) | 1980-11-10 | 1985-05-02 | Gersonde Klaus | Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
DE3483949D1 (de) | 1983-09-26 | 1991-02-21 | Udo Dr Med Ehrenfeld | Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr. |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
DK15888D0 (da) | 1988-01-14 | 1988-01-14 | Carlsberg Biotechnology Ltd | Enzymatisk fremgangsmaade til fremstilling af immunmodulerende pentapeptider samt mellemprodukter til brug ved fremgangsmaaden |
SE8803847A0 (sv) | 1988-10-27 | 1990-04-28 | Kabigen Ab | Neuromodulerande peptid |
EP0735894A4 (en) | 1993-12-23 | 1999-08-18 | Auckland Uniservices Ltd | COMPOSITION AND METHODS FOR IMPROVING THE OUTCOME OF NERVOUS SYSTEM CONDITIONS |
WO1995032003A1 (en) | 1994-05-24 | 1995-11-30 | Amgen Boulder Inc. | Modified insulin-like growth factors |
AU743412B2 (en) | 1996-10-04 | 2002-01-24 | Neuren Pharmaceuticals Limited | Regulation of neural enzymes |
CA2334528A1 (en) | 1998-06-15 | 1999-12-23 | Peter David Gluckman | Regulation of tyrosine hydroxylase |
ES2250211T3 (es) * | 1999-10-26 | 2006-04-16 | Janssen Pharmaceutica N.V. | Disolucion oral que contiene galantamina y un agente edulcorante. |
WO2002016408A2 (en) | 2000-08-24 | 2002-02-28 | Neuronz Ltd. | Gpe analogs |
US7863304B2 (en) | 2001-05-24 | 2011-01-04 | Neuren Pharmaceuticals Limited | Analogs of glycyl-prolyl-glutamate |
US20070004641A1 (en) | 2001-05-24 | 2007-01-04 | Neuren Pharmaceuticals Limited | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate |
JP2004536069A (ja) * | 2001-05-24 | 2004-12-02 | ニューロンズ・リミテッド | Gpe類縁体及びペプチドミメティック |
US7605177B2 (en) * | 2001-05-24 | 2009-10-20 | Neuren Pharmaceuticals Limited | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration |
US7714020B2 (en) | 2001-05-24 | 2010-05-11 | Neuren Pharmaceuticals Limited | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate |
US8637567B2 (en) | 2001-05-24 | 2014-01-28 | Neuren Pharmaceuticals Ltd. | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid |
US7714070B2 (en) | 2002-08-27 | 2010-05-11 | Sunoco Chemicals, Inc. | In-reactor produced polypropylene blends |
ATE506945T1 (de) | 2004-09-20 | 2011-05-15 | Sinai School Medicine | Verwendung von memantin (namenda) zur behandlung von autismus, zwangsverhalten und impulsivität |
JP2008545697A (ja) * | 2005-05-23 | 2008-12-18 | ニューレン ファーマシューティカルズ リミテッド | グリシル−プロリル−グルタメートの類縁体 |
ES2487493T3 (es) * | 2006-03-14 | 2014-08-21 | Neuren Pharmaceuticals Limited | Formulaciones orales de glicil-2-metilprolil-glutamato |
GB0707127D0 (en) * | 2007-04-13 | 2007-05-23 | Zysis Ltd | Pharmaceutical compositions |
WO2008153929A1 (en) | 2007-06-08 | 2008-12-18 | Massachusetts Institute Of Technology | Igf for the treatment of rett syndrome and synaptic disorders |
TW200932233A (en) * | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
JP2011529072A (ja) | 2008-07-24 | 2011-12-01 | セラヴァンス, インコーポレーテッド | 二重作用血圧降下薬 |
KR20110114664A (ko) | 2009-01-16 | 2011-10-19 | 메사추세츠 인스티튜트 오브 테크놀로지 | 자폐 스펙트럼 장애의 진단 및 치료 |
ES2617309T3 (es) | 2010-05-17 | 2017-06-16 | Icahn School Of Medicine At Mount Sinai | Métodos y ensayos de tratamiento de sujetos con eliminación, mutación o expresión reducida de SHANK3 |
RS56461B1 (sr) | 2011-01-27 | 2018-01-31 | Neuren Pharmaceuticals Ltd | Tretman bolesti iz spektra autizma upotrebom glicil-l-2-metilprolil-l-glutaminske kiseline |
-
2012
- 2012-01-27 RS RS20171001A patent/RS56461B1/sr unknown
- 2012-01-27 LT LTEP12739509.3T patent/LT2667715T/lt unknown
- 2012-01-27 BR BR112013018898-7A patent/BR112013018898B1/pt active IP Right Grant
- 2012-01-27 CA CA2823218A patent/CA2823218C/en active Active
- 2012-01-27 US US13/699,087 patent/US9708366B2/en active Active
- 2012-01-27 EP EP12739509.3A patent/EP2667715B1/en active Active
- 2012-01-27 SI SI201231075T patent/SI2667715T1/sl unknown
- 2012-01-27 JP JP2013551979A patent/JP6348283B2/ja active Active
- 2012-01-27 PL PL12739509T patent/PL2667715T3/pl unknown
- 2012-01-27 AU AU2012209466A patent/AU2012209466C1/en active Active
- 2012-01-27 WO PCT/US2012/000047 patent/WO2012102832A1/en active Application Filing
- 2012-01-27 HU HUE12739509A patent/HUE036637T2/hu unknown
- 2012-01-27 ES ES12739509.3T patent/ES2641880T3/es active Active
- 2012-01-27 DK DK12739509.3T patent/DK2667715T3/en active
- 2012-01-27 PT PT127395093T patent/PT2667715T/pt unknown
-
2013
- 2013-07-25 IL IL227669A patent/IL227669B/en active IP Right Grant
- 2013-08-23 CO CO13200227A patent/CO6791613A2/es not_active Application Discontinuation
-
2015
- 2015-01-26 US US14/605,420 patent/US9212204B2/en active Active
-
2016
- 2016-09-09 JP JP2016176567A patent/JP6342459B2/ja active Active
-
2017
- 2017-10-04 HR HRP20171478TT patent/HRP20171478T1/hr unknown
- 2017-10-12 CY CY20171101074T patent/CY1119455T1/el unknown
-
2018
- 2018-05-16 JP JP2018094320A patent/JP6640275B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
US20140147491A1 (en) | 2014-05-29 |
DK2667715T3 (en) | 2017-10-23 |
AU2012209466B2 (en) | 2016-02-25 |
RS56461B1 (sr) | 2018-01-31 |
EP2667715A4 (en) | 2014-07-23 |
JP2014508744A (ja) | 2014-04-10 |
LT2667715T (lt) | 2017-11-10 |
JP6342459B2 (ja) | 2018-06-13 |
AU2012209466A1 (en) | 2013-09-05 |
JP6348283B2 (ja) | 2018-06-27 |
HUE036637T2 (hu) | 2018-07-30 |
SI2667715T1 (sl) | 2017-11-30 |
PT2667715T (pt) | 2017-10-19 |
AU2012209466C1 (en) | 2016-06-23 |
JP6640275B2 (ja) | 2020-02-05 |
EP2667715A1 (en) | 2013-12-04 |
JP2016210808A (ja) | 2016-12-15 |
HRP20171478T1 (hr) | 2017-11-17 |
CA2823218C (en) | 2021-04-20 |
CO6791613A2 (es) | 2013-11-14 |
US20150197543A1 (en) | 2015-07-16 |
ES2641880T3 (es) | 2017-11-14 |
CY1119455T1 (el) | 2018-04-04 |
US9212204B2 (en) | 2015-12-15 |
EP2667715B1 (en) | 2017-07-19 |
IL227669B (en) | 2020-06-30 |
WO2012102832A1 (en) | 2012-08-02 |
CA2823218A1 (en) | 2012-08-02 |
BR112013018898A2 (pt) | 2017-04-18 |
BR112013018898B1 (pt) | 2021-10-05 |
IL227669A0 (en) | 2013-09-30 |
JP2018138606A (ja) | 2018-09-06 |
US9708366B2 (en) | 2017-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LT2667715T (lt) | Autizmo spektro susirgimų gydymas, naudojant glicil-l-2-metilprolil-l-glutamo rūgštį | |
EP2723384A4 (en) | TREATMENT OF PROTEINOPATHIES | |
IL226401A0 (en) | Methods for treating disorders related to @fgfBA | |
EP2773754A4 (en) | Methods of Treatment | |
EP2717855A4 (en) | PROCESSING METHODS | |
ZA201205829B (en) | Treatment of respiratory disorders | |
HK1199015A1 (en) | Treatment of inflammation | |
EP2773212A4 (en) | METHODS AND COMPOSITIONS USED FOR THE TREATMENT OF AUTISM | |
HK1199261A1 (en) | Methods for treatment of diseases | |
GB201202773D0 (en) | Compositions for treatment of skin disorders | |
EP2704723A4 (en) | TREATMENT OF POLYCYSTIC DISEASES | |
IL225896A0 (en) | Treatment of mecp-2 related disorders | |
EP2709665A4 (en) | TREATMENT OF PSORIASIS | |
PL395112A1 (pl) | Zastosowanie klenbuterolu do leczenia autyzmu | |
EP2638038A4 (en) | METHOD OF TREATING MENTAL DISORDERS | |
EP2928300A4 (en) | TREATMENT OF AUTISTIC SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID | |
GB201107467D0 (en) | Novel treatment of pain | |
EP2791324A4 (en) | PROCESSING METHOD | |
GB201218263D0 (en) | Treatment of autism | |
GB201101773D0 (en) | Treatment of inflammatory disorders | |
GB201101183D0 (en) | Treatment of neurodegenerative disorders | |
GB201100651D0 (en) | Treatment of inflammation | |
GB201119458D0 (en) | Compositions for treatment of sleep disorders | |
GB201118065D0 (en) | Treatment of movement disorders | |
GB201110602D0 (en) | Methods of treatment |